Elevated TWEAK reflects psoriasis and PsA activity. Adalimumab and methotrexate reduce TWEAK alongside clinical improvement, supporting its potential as a biomarker for treatment monitoring. Key Points • Serum TWEAK levels were substantially elevated in psoriasis and psoriatic arthritis patients in comparison to controls. • TWEAK levels decreased following treatment with methotrexate and adalimumab. • Clinical improvement and disease activity scores were positively correlated with a decrease in TWEAK levels. • TWEAK may be a valuable biomarker for the monitoring of treatment response in psoriasis.
Hegazy et al. (Wed,) studied this question.